UNITED STATESSECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 11, 2017
INVO BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)
Nevada | | 333-147330 | | 20-4036208 |
| (State or other jurisdiction of | | (Commission | | (I.R.S. Employer |
| Incorporation) | | File Number) | | Identification No.) |
407R Mystic Avenue, Suite 34C, Medford, MA 02155
(Address of principal executive offices) (Zip Code)
(978) 878-9505
(Registrant’s telephone number, including area code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| | | |
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| | | |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| | |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 FR 240.13e-4(c)) |
INVO Bioscience, Inc. (the “Company”) is furnishing this Amendment No. 1 to its Current Report on Form 8-K (“Amendment No. 1”) furnished with the SEC on April 10, 2017 (the “Original Form 8-K”), pursuant to Item 5.02(a)(3)(iii) which requires the Company to file any letter received from the director. Attached is the letter INVO Bioscience received.
| Item 9.01 | Financial Statements and Exhibits |
| Exhibit Number | | Description |
| 17.1 | | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | INVO Bioscience, Inc. | |
| | | | |
| Date: April 13, 2017 | By: | /s/ Kathleen T. Karloff | |
| | | Kathleen T. Karloff | |
| | | Chief Executive Officer and Chairman of the Board of Directors | |
| | | | |
